Bicalutamide Requires Combination with LHRH Analog (GnRH Agonist/Antagonist)
Bicalutamide must be combined with a luteinizing hormone-releasing hormone (LHRH) analog—either an LHRH agonist (such as leuprolide or goserelin) or an LHRH antagonist (such as degarelix)—to achieve combined androgen blockade in prostate cancer treatment. 1
FDA-Approved Indication
The FDA label explicitly states that bicalutamide 50 mg is indicated "for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate." 1 The label emphasizes that bicalutamide 150 mg daily is NOT approved for use alone or with other treatments. 1
Clinical Rationale
This combination creates what is termed "combined androgen blockade" (CAB) or "maximal androgen blockade" (MAB):
- LHRH analogs achieve medical castration by suppressing testicular testosterone production
- Bicalutamide blocks residual androgens (from adrenal sources and intratumoral production) at the androgen receptor level
The dual mechanism addresses both sources of androgen stimulation driving prostate cancer growth.
Guideline Support
Current ASCO guidelines 2 recommend that in resource-constrained settings where newer agents like abiraterone are unavailable, combined androgen blockade using ADT (LHRH analog) plus a first-generation antiandrogen such as bicalutamide may be offered for locally advanced nonmetastatic prostate cancer rather than castration monotherapy. This recommendation is based on high-quality evidence from meta-analyses showing improved overall survival (HR: 0.88,95% CI 0.82-0.95, P=0.0009) and progression-free survival with CAB using nonsteroidal antiandrogens. 2
Evidence Base
Multiple studies confirm the necessity of this combination:
- A Japanese phase 3 trial demonstrated that bicalutamide 80 mg combined with an LHRH agonist achieved 79.4% PSA normalization at 12 weeks versus only 38.6% with LHRH agonist monotherapy (P<0.001) 3
- Long-term follow-up (median 5.2 years) showed significant overall survival advantage for CAB with bicalutamide versus LHRH agonist alone (HR: 0.78,95% CI 0.60-0.99, P=0.0498) 4
- A large randomized trial confirmed equivalent efficacy between bicalutamide and flutamide when each was combined with LHRH analog therapy 5
Common Pitfall to Avoid
Never use bicalutamide as monotherapy for metastatic prostate cancer. The FDA specifically states that the 150 mg dose is not approved for use alone, and the 50 mg dose requires combination with an LHRH analog. 1 Bicalutamide alone will not suppress testosterone levels and may even increase them through loss of negative feedback, making it ineffective as monotherapy for advanced disease.
Practical Implementation
When prescribing bicalutamide: